Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Multidisciplinary Collaboration

April 19th 2025

In this episode, experts discuss the landmark SARC 032 study, highlighting the importance of multidisciplinary collaboration.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Impact of Immunotherapy on Surgical Planning

April 18th 2025

In this episode, experts discuss the impact of neoadjuvant radiation and immunotherapy on surgical planning in patients with soft tissue sarcomas.

Belantamab Mafodotin–Based Combos Win UK Approval for R/R Myeloma

April 17th 2025

Two belantamab mafodotin–based combinations have been approved in the United Kingdom for relapsed/refractory multiple myeloma.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Surgical Oncology Goals

April 17th 2025

In this episode, experts shed light on the surgical approach to soft tissue sarcomas.

Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia

April 17th 2025

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Radiation Oncology and Immune Stimulation

April 16th 2025

In this episode, experts discuss the potential of radiation therapy to enhance immune response in soft tissue sarcomas.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Trial Design and Key Data

April 15th 2025

In this episode, experts discuss the rationale behind the combined treatment in the Stand Up to Cancer SARC 032 trial.

CEPHEUS Data Support D-VRd in Transplant-Ineligible or -Deferred Patients With Myeloma Who Can Tolerate Bortezomib

April 13th 2025

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma

April 12th 2025

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Educational Intervention Seeks to Decrease Barriers to Cancer Clinical Trial Enrollment

April 11th 2025

Cancer clinical trial education is valuable and may promote current and future participation.

Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX

April 10th 2025

The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.

Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC

April 10th 2025

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa

April 9th 2025

Phase 1b data support further exploration of intravenous sirolimus in patients with malignant PEComa.

Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC

April 9th 2025

Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC

April 8th 2025

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC

April 7th 2025

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.